SHIFT Newsroom · GLOBAL
GLP-1 treatments and MASH fibrosis: a review of the evidence
This review discusses evidence for GLP-1-based treatments in MASH-related fibrosis. Results come from the studies it reviews; it is not a new treatment trial. Different agents have different evidence and regulatory status. UK authorisation and NHS access need separate current official checks.
What the source says
This review discusses evidence for GLP-1-based treatments in MASH-related fibrosis. Results come from the studies it reviews; it is not a new treatment trial. Different agents have different evidence and regulatory status. UK authorisation and NHS access need separate current official checks.
Evidence and limits
The authors review mechanisms and phase 2 and phase 3 trials with liver-tissue outcomes. Their discussion includes US regulatory decisions. Different medicines and combinations need their own evidence; a research programme is not a UK treatment offer.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
A research update about liver disease is not a reason to choose or change a weight-management medicine. Liver assessment and treatment decisions belong with the treating clinical team.
Known facts
- This review discusses evidence for GLP-1-based treatments in MASH-related fibrosis.